Did you know that Massachusetts added nearly 3,000 biopharma jobs in 2023? Were you aware that $28.9 billion was spent acquiring Massachusetts biotechs in just the first six months of this year? Did you know that Massachusetts has a higher percentage of advanced modalities in its drug pipeline than any direct competitor? Discover the latest data on the Commonwealth’s #lifesciences industry and hear from leading industry stakeholders in this year’s Industry Snapshot: https://lnkd.in/e8Wdfkzy. #MassBioIndustrySnapshot #biopharma #lifesciences #patientdriven
MassBio
Biotechnology Research
Cambridge, Massachusetts 34,107 followers
Massachusetts is the State of Possible - the #1 life sciences cluster in the world - and we plan to keep it that way!
Über uns
MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts life sciences industry, is the nation's oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives. Representing more than 1000 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and healthcare, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.
- Website
-
http://www.massbio.org
External link for MassBio
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 11-50 Mitarbeiter
- Hauptsitz
- Cambridge, Massachusetts
- Typ
- Nonprofit
- Gegründet
- 1985
Standorte
-
Primäre
700 Technology Sq
5. Stockwerk
Cambridge, Massachusetts 02139, US
Employees at MassBio
-
Carolina Alarco
Biotech/Medtech Executive and Board Member, Strategic Consultant, Investment Banking, Angel Investor
-
Joel Kahn MD, NBC-HWC
Innovation driven health executive
-
Joseph Murphy
Founder and President at immunePCS, LLC
-
Rita McAteer
Accomplished marketing, communications and fundraising leader.
Aktualisierungen
-
#FundingFriday: A mix of seed, angel, early and late stage funding announcements this week totaling more than $278M dollars: Abata Therapeutics, Convergent Therapeutics, Inc., Elektrofi, Exa Biosciences, Judo Bio, Kano Therapeutics, Odyssey Therapeutics, Psy Therapeutics, Inc, and Tenza. Congrats on the raises! Kano, a MIT spinout leveraging single strand DNA to ‘bridge the gap’ between gene editing and gene replacement, raised $5M in seed funds primarily from Engine Ventures and inked a partnership with Novo Nordisk (Story: https://lnkd.in/eKcHzri7). While we're on the subject on funding, breaking news on Thursday that #MassBioMembers Bicara Therapeutics and Zenas BioPharma plan to go public, marking the third and fourth IPOs of the year for companies based in Massachusetts. More from Hannah Green in the BBJ: https://lnkd.in/eAMm2fCe.
-
No greater advocate for the Commonwealth's leadership in the #lifesciences than Governor Healey. Novo Nordisk recognizes what has been built here through collaboration and partnerships over many years, and that's why they've expanded here ... to tap into the talent and the innovation. #MassBioMember
Welcoming Massachusetts Governor Maura Healey to our Novo Nordisk R&D Hub was the highlight of my week. It was a privilege to speak to Governor Healey about Novo Nordisk’s more than 100-year incredible history, our commitment to finding treatment for serious chronic diseases, reducing our environmental impact and show her our state-of-the-art labs here in Lexington. During the lab tour she meet a lot of our scientists and showed an interest in not only what we do, but also in who we are and where we all live, are from, and went to school. It was an incredible experience to have a politician that demonstrates genuine interest which left many of our scientist (including myself) star struck. The commitment Governor Healey has to the life sciences community is paramount to the amazing ecosystem here in Boston. We appreciate all her dedication and support and hope that together are able to make the ecosystem even better.
-
-
We asked 10 questions, and the #MassBioHub team gave us the answers. Have a big event and want a full buyout? They can do that. Just need an office for a day? Hot desking is the way. Want a holiday-themed party with spirit-filled food? The Jingle & Mingle package has you covered. More on the blog: https://lnkd.in/e_ifQVsw. Want to experience the Hub in person and ask your own questions? Come to the Hub Open House on September 12 for a tour, food and drink tasting, and more. Register here: https://lnkd.in/eE56JNbA. #KendallSquare #CambridgeMA #ElevatedMeetings
-
-
We've been busy in the #MassBioHub this summer - hosting company events, lunch and learns, and offsite meetings! Thank you to all of the organizations hosting events with us. Curia | Korro Bio, Inc. | Myeloid Therapeutics If you've ever been curious to try out our space for your next meeting, stop by our Open House on Thursday, September 12.🏠 Register: https://lnkd.in/eE56JNbA
-
-
Comments from MassBio CEO & President Kendalle Burlin O'Connell, Esq. on today's Centers for Medicare & Medicaid Services release of the prices for the first ten drugs subject to the IRA's Medicare Drug Price Negotiation Progam.
CEO & President, MassBio | Chair, Bioversity | Board, The Boston Foundation | Vice Chair, American Cancer Society (ACS) Eastern New England | Board, MassBioEd Foundation
Today CMS released prices for the first ten drugs subject to the IRA’s Medicare Drug Price Negotiation Program. The prices released today are the result of a flawed law that disincentivizes the development of new cures, therapies, and vaccines. MassBio remains concerned about the law and is committed to working with policymakers to develop alternative solutions that encourage patient access to innovative new therapies.
-
We are in the dog days of August – join us in welcoming the newest members of the MassBio community: ⚖️ Crossroads Regulatory Consulting provides expert consulting services that empower organizations to navigate complex regulatory landscapes with confidence, ensuring compliance, assessing risk, and optimizing operational efficiency. 💊 Cytokinetics is a late-stage biopharmaceutical company committed to developing potential medicines that may improve the healthspan of people living with cardiovascular and neuromuscular diseases of impaired muscle function. 💡 Harbor Clinical, a niche CRO with a suite of software solutions, has a team of highly specialized talent to support clinical trial needs. 🧬 MedTherapy Biotech is a Boston-based end-to-end, integrated CAR-T Cell CDMO, with commercial scale GMP manufacturing facility in New Delhi, India and technology development site at Boston. #MassBioMembers #CDMO #CRO #biopharma #regulations
-
MassBio reposted this
CEO & President, MassBio | Chair, Bioversity | Board, The Boston Foundation | Vice Chair, American Cancer Society (ACS) Eastern New England | Board, MassBioEd Foundation
Great to see the central Massachusetts love on WCVB Channel 5's Chronicle in this spotlight on the remarkable rebirth of Devens. Breweries, housing, cleantech, #biomanufacturing - all being made in a way that builds community. What was music to my ears? King Street Properties's Tyson Reynoso talking about the "high-paying, next generation jobs" at Devens and the fact that "you can keep manufacturing in Massachusetts, it doesn't have to go to other states." YES! https://lnkd.in/eHqE8kNx Kelly Arvidson | MassDevelopment | Pathway Devens | Azzur Group
Former Fort Devens in Mass. is transforming into a lively community
https://www.youtube.com/
-
This summer's MassBio Member Spotlight features Rhythm Pharmaceuticals Inc.. Join MassBio CEO & President Kendalle Burlin O'Connell, Esq. for a wide-ranging conversation with David Meeker, CEO, President, and Chairman of Rhythm. You can watch the full interview, which touches on patients, the Massachusetts ecosystem, challenges to innovation, and more, on the blog: https://lnkd.in/ee3DGFys. #MassBioMember #patientdriven
-
Let's talk #fundingfriday and the more than $500M in VC dollars that were reported by local biotechs the last few weeks. AIRNA, Artax Biopharma Inc, Diceros Therapeutics, Endolytix, IDRx, Jade Biosciences, PineTree Therapeutics Inc, Red Queen Therapeutics, Scipher Medicine, and Vedanta Biosciences, Inc.. Some highlights: 🔴 Red Queen emerged from stealth with $55M and technology licensed from Dana-Farber Cancer Institute to prevent viruses from fusing with cells in the human body. https://lnkd.in/eYYe6FUw 🟢 Jade Bioscience will use $80M in financing to help advance its mission to deliver potentially best-in-class therapies for patients living with autoimmune diseases. https://lnkd.in/e7q8vzES 🟣 Plymouth-based IDRx will puts its $120M in Series B financing to use advancing a potential best-in-class new treatment for Gastrointestinal Stromal Tumor (GIST). https://lnkd.in/g2wmSj96 🔵 Boston-based AIRNA, an RNA editing startup, is adding more funds to its Series A round, raising another $60M as it develops genetic medicines for lung, cardiovascular, metabolic and blood diseases. https://lnkd.in/edgHc5Bc #MassBioMembers